Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effect of Recording Duration on Heart Rate Variability During taVNS

NCT07526415 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-05-01
Last updated
2026-04-16

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

Transcutaneous Auricular Vagus Nerve StimulationSham Stimulation

Transcutaneous Auricular Vagus Nerve Stimulation: Active transcutaneous auricular vagus nerve stimulation will be applied bilaterally to the cymba conchae region of the ear using a transcutaneous stimulation device. Stimulation will be delivered for 10 minutes with a frequency of 25 Hz, a pulse width of 200 to 300 microseconds, and an individually adjusted intensity that is clearly perceptible but not painful. Heart rate variability will be recorded continuously during the intervention.

Sham Stimulation: Sham stimulation will be delivered for 10 minutes using the same transcutaneous stimulation device and similar stimulation settings as the active intervention, but the stimulation will be applied to a non-vagal ear region, such as the earlobe or helix, to minimize physiologic vagal effects while maintaining similar sensory input. Heart rate variability will be recorded continuously during the intervention.

Study summary

This study aims to evaluate how different heart rate variability (HRV) recording durations reflect autonomic nervous system responses during transcutaneous auricular vagus nerve stimulation (taVNS) in healthy adults. In a randomized, sham-controlled crossover design, participants will attend two separate sessions and receive both active taVNS and sham stimulation in randomized order. During each session, a continuous 10-minute HRV recording will be obtained, and 1-minute, 5-minute, and 10-minute analysis windows will be compared. Blood pressure and pulse will also be measured before and after stimulation. The study will investigate whether shorter or longer HRV recording durations provide results comparable to the standard 5-minute recording and which duration most reliably detects autonomic changes during taVNS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy volunteers aged 18 to 40 years * Able and willing to provide informed consent * Able to tolerate active transcutaneous auricular vagus nerve stimulation and sham stimulation * Able to comply with study instructions, including restrictions related to caffeine, nicotine, and heavy exercise before assessment * No condition preventing heart rate variability, blood pressure, or pulse measurements Exclusion Criteria: * Diagnosed cardiovascular disease, arrhythmia, or pacemaker use * History of neurologic disease that may affect autonomic nervous system function * Regular use of medications that may affect heart rate variability or autonomic responses, including beta blockers, antiarrhythmics, or anticholinergic drugs * Active ear infection, dermatologic lesion, or any ear condition that may interfere with stimulation * Marked pain, discomfort, or intolerance during stimulation * Acute infection, fever, or other acute health problem on the measurement day * Heart rate variability data that cannot be evaluated because of excessive motion artifact

Primary outcome measure(s)

  • Difference in 5-minute lnRMSSD During Active taVNS Compared With Sham Stimulation — During the 10-minute intervention period at each study session
    The primary outcome is the between-condition difference in 5-minute heart rate variability, assessed by lnRMSSD derived from the continuous RR interval recording obtained during the 10-minute intervention period. The 5-minute analysis window is the prespecified standard short-term HRV measure used to compare active transcutaneous auricular vagus nerve stimulation with sham stimulation.

Trial sites (1)

FacilityCityRegionStatus
Artvin Coruh University, Artvin Vocational School, Disabled Care and Rehabilitation Laboratory, Artvin, Artvin Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07526415 on ClinicalTrials.gov ↗ ← All trials in Turkey